| Ridley Corporation Limited (RIC) ORDINARY FULLY PAID |
Consumer Staple |
$1,031 |
FY25 Full Year Results Investor Presentation
|
21 Aug 2025 8:32AM |
$2.910 |
$2.750 |
fallen by
5.50%
|
|
RIC - Price-sensitive ASX Announcement
Full Release
Key Points
- Reviewed FY25 full year financial results including revenue and EBITDA performance.
- Outlined operational highlights and achievements across business segments.
- Presented updates on significant capital projects and infrastructure investments.
- Discussed market conditions and their impact on Ridley’s business.
- Detailed progress in sustainability initiatives and innovation projects.
- Provided outlook and guidance for the upcoming financial year.
- Summarized dividends, shareholder returns, and capital management strategies.
- Emphasized focus on operational improvement and customer engagement.
- Highlighted strategic priorities including new product development and market expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pengana International Equities Limited (PIA) ORDINARY FULLY PAID |
Financials |
$344 |
PIA Proposed Enhancements to Portfolio and Dividends
|
21 Aug 2025 8:32AM |
$1.220 |
$1.335 |
risen by
9.43%
|
|
PIA - Price-sensitive ASX Announcement
Full Release
Key Points
- PIA proposes a more concentrated, high-conviction global equities portfolio.
- Portfolio changes include fewer holdings, higher active share, and an emphasis on fundamental research.
- The Board intends to refine the investment process to enhance capital growth and risk-adjusted returns.
- An enhanced dividend policy is proposed, focusing on regular and sustainable distributions to shareholders.
- Dividend enhancements will be subject to profit reserves and prudent capital management.
- Shareholder feedback is being sought on the proposed changes.
- Board reaffirms its commitment to transparency, alignment with shareholder interests, and maintaining performance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pengana Capital Group Limited (PCG) ORDINARY FULLY PAID |
Financials |
$83 |
PIA Proposed Enhancements to Portfolio and Dividends
|
21 Aug 2025 8:32AM |
$0.795 |
$0.845 |
risen by
6.29%
|
|
PCG - Price-sensitive ASX Announcement
Full Release
Key Points
- PCG announced enhancements to PIA portfolio and dividend policy.
- Introduction of a new international ethical investment strategy.
- Focus on a concentrated portfolio of the best global ethical ideas.
- Aim to deliver stronger risk-adjusted returns.
- Management by an experienced investment team.
- Proposed dividend policy targets higher and more stable dividends.
- Rationale and expected benefits of changes are outlined.
- Shareholder approval is required for implementation.
- Implementation timeline is provided in the announcement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Canterbury Resources Ltd (CBY) ORDINARY FULLY PAID |
Materials |
$11 |
Share Purchase Plan
|
21 Aug 2025 8:32AM |
$0.021 |
$0.041 |
risen by
95.24%
|
|
CBY - Price-sensitive ASX Announcement
Full Release
Key Points
- Canterbury Resources Ltd announced a Share Purchase Plan (SPP) to raise capital.
- The SPP offers existing eligible shareholders the opportunity to purchase additional shares at a fixed price without brokerage fees.
- The document details eligibility, application process, and offer period for the SPP.
- Funds raised will support the company's exploration and development projects, with emphasis on Papua New Guinea assets.
- The SPP describes key risks, tax implications, and participant responsibilities.
- Shareholders are advised to review the information carefully and consider personal financial circumstances before applying.
- The key dates and instructions for applying to the SPP are specified within the document.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ridley Corporation Limited (RIC) ORDINARY FULLY PAID |
Consumer Staple |
$1,031 |
Dividend/Distribution - RIC
|
21 Aug 2025 8:32AM |
$2.910 |
$2.750 |
fallen by
5.50%
|
|
| Redox Limited (RDX) ORDINARY FULLY PAID |
Industrials |
$1,901 |
Dividend/Distribution - RDX
|
21 Aug 2025 8:31AM |
$2.100 |
$3.620 |
risen by
72.38%
|
|
| Redox Limited (RDX) ORDINARY FULLY PAID |
Industrials |
$1,901 |
Redox 2025 Corporate Governance Statement
|
21 Aug 2025 8:31AM |
$2.100 |
$3.620 |
risen by
72.38%
|
|
| Redox Limited (RDX) ORDINARY FULLY PAID |
Industrials |
$1,901 |
Redox FY25 Results Presentation
|
21 Aug 2025 8:31AM |
$2.100 |
$3.620 |
risen by
72.38%
|
|
RDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Redox Limited reported robust revenue growth and improved financial performance for FY25.
- EBITDA and NPAT both experienced year-over-year increases, attributed to higher sales volumes and margin improvements.
- Geographic expansion and sector diversification contributed positively to the company’s results.
- Operational efficiencies were realized through supply chain optimization and process digitalization.
- Strategic investments were made in infrastructure and technology to support future growth.
- The company advanced its sustainability and ESG initiatives, including emissions reduction and responsible sourcing.
- Risk management practices were strengthened to address market volatility and supply chain disruptions.
- The outlook for FY26 remains positive, with ongoing investments in growth and innovation expected to drive continued success.
- Shareholder engagement and communication remain a priority, with a focus on transparency and long-term value creation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Peter Warren Automotive Holdings Limited (PWR) ORDINARY FULLY PAID |
Consumer Discretionary |
$170 |
Dividend/Distribution - PWR
|
21 Aug 2025 8:31AM |
$1.860 |
$0.985 |
fallen by
47.04%
|
|
| Ridley Corporation Limited (RIC) ORDINARY FULLY PAID |
Consumer Staple |
$1,031 |
Preliminary Final Report
|
21 Aug 2025 8:30AM |
$2.910 |
$2.750 |
fallen by
5.50%
|
|
RIC - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory Net Profit After Tax for the year ended 30 June 2023 was $25.4 million, underlying Net Profit After Tax was $31.7 million.
- Underlying EBITDA increased by 6% to $81.0 million compared to the prior year.
- Final dividend of 3.0 cents per share was declared, making a total fully franked full-year dividend of 6.0 cents per share.
- Sales revenue for the year was $1,320.0 million, a 9% increase from the previous year.
- The Animal Nutrition segment delivered higher earnings due to operational improvements and cost recovery initiatives.
- The Ingredients segment saw EBITDA growth driven by new customer contracts and increased volumes in aquafeed.
- Completion and commissioning of the new Tasmanian extrusion plant contributed to aquafeed growth.
- No significant changes in the state of affairs other than those detailed in the report.
- After balance date, no matters or circumstances have arisen that would significantly affect the company's operations or financial results.
- The company continues to focus on growth opportunities, operational efficiency, and risk management for future performance.
- Details on share capital, remuneration of directors and key management personnel, and statutory disclosures are included.
- Auditor’s independence declaration and compliance with corporate governance practices are provided.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ventia Services Group Limited (VNT) ORDINARY FULLY PAID |
Industrials |
$4,866 |
Update - Notification of buy-back - VNT
|
21 Aug 2025 8:30AM |
$5.490 |
$5.950 |
risen by
8.38%
|
|
| MAAS Group Holdings Limited (MGH) ORDINARY FULLY PAID |
Industrials |
$2,013 |
Corporate Governance Statement 2025
|
21 Aug 2025 8:30AM |
$4.280 |
$5.570 |
risen by
30.14%
|
|
| Acumentis Group Limited (ACU) ORDINARY FULLY PAID |
Real Estate |
$17 |
Dividend/Distribution - ACU
|
21 Aug 2025 8:30AM |
$0.070 |
$0.078 |
risen by
11.43%
|
|
| MAAS Group Holdings Limited (MGH) ORDINARY FULLY PAID |
Industrials |
$2,013 |
Dividend/Distribution - MGH
|
21 Aug 2025 8:29AM |
$4.280 |
$5.570 |
risen by
30.14%
|
|
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$5,522 |
Telix H1 2025 Results Presentation
|
21 Aug 2025 8:29AM |
$16.920 |
$16.270 |
fallen by
3.84%
|
|
TLX - Price-sensitive ASX Announcement
Full Release
Key Points
- Telix global revenue increased by 63% year-over-year in H1 2025.
- The company's gross margin reflects a change in the product mix and strategic investments.
- There is a significant investment in commercial infrastructure and R&D, focusing on strategic growth opportunities.
- Precision Medicine segment reported a 24% increase in EBITDA, with ongoing investments in commercial performance.
- Telix is advancing its pipeline in urologic and neurologic oncology, including several first-in-class therapies.
- The company achieved global regulatory approvals for various products, with Illuccix showing significant growth and market penetration.
- Telix's financial strategy aligns with growth opportunities, focusing on commercial infrastructure and therapeutic pipeline development.
- The company's FY 2025 guidance remains maintained, with expectations of continued growth through product and geographic expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$5,522 |
Telix H1 2025 Results Presentation
|
21 Aug 2025 8:29AM |
$16.920 |
$16.270 |
fallen by
3.84%
|
|
TLX - Price-sensitive ASX Announcement
Full Release
Key Points
- Telix's revenue increased by 63% YoY to $390.4 million in H1 2025.
- Illuccix® continues to be a key driver of revenue growth.
- Significant investment in R&D, with a 47% increase YoY.
- Expansion of global manufacturing operations, including integration of RLS.
- On track to meet FY 2025 revenue guidance of $770M - $800M.
- Advancements in clinical trials for oncology therapeutics.
- Continued investment in precision medicine and commercial infrastructure.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pengana International Equities Limited (PIA) ORDINARY FULLY PAID |
Financials |
$344 |
PIA Corporate Timetable
|
21 Aug 2025 8:29AM |
$1.220 |
$1.335 |
risen by
9.43%
|
|
| Artrya Limited (AYA) ORDINARY FULLY PAID |
Health Care |
$940 |
FDA clearance of Salix Coronary Plaque module
|
21 Aug 2025 8:29AM |
$1.300 |
$5.770 |
risen by
343.85%
|
|
AYA - Price-sensitive ASX Announcement
Full Release
Key Points
- Artrya Limited announced FDA 510(k) clearance for its Salix Coronary Plaque (SCP) module.
- The SCP module uses AI to detect and quantify coronary atherosclerotic plaque.
- FDA clearance enables commercialization of the SCP module in the United States.
- The technology provides clinicians with detailed plaque characterization to aid in coronary artery disease management.
- The FDA approval is a strategic milestone for Artrya, validating its technology and supporting U.S. market entry.
- Coronary artery disease is a major health issue and the SCP module addresses a significant clinical need.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Redox Limited (RDX) ORDINARY FULLY PAID |
Industrials |
$1,901 |
Redox FY25 Results Announcement
|
21 Aug 2025 8:29AM |
$2.100 |
$3.620 |
risen by
72.38%
|
|
RDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Redox Limited reported strong revenue growth and improved profitability for FY25.
- Expansion occurred in both domestic and international markets.
- The company’s performance was driven by effective supply chain management and strategic acquisitions.
- Redox maintained a diversified product portfolio focused on specialty chemical distribution.
- Management highlighted sustainability, customer relationships, and innovation as strategic priorities.
- Challenges included inflationary pressures and global supply disruptions.
- Redox implemented mitigation strategies to address operational challenges.
- The outlook for FY26 is positive with plans for further investment in technology, infrastructure, and talent.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pengana International Equities Limited (PIA) ORDINARY FULLY PAID |
Financials |
$344 |
Appendix 4G 30 June 2025
|
21 Aug 2025 8:28AM |
$1.220 |
$1.335 |
risen by
9.43%
|
|
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$5,522 |
Telix H1 2025 Results Announcement
|
21 Aug 2025 8:28AM |
$16.920 |
$16.270 |
fallen by
3.84%
|
|
TLX - Price-sensitive ASX Announcement
Full Release
Key Points
- Telix Pharmaceuticals reported a 63% increase in revenue for H1 2025, reaching $390.4 million.
- The company maintained a gross profit margin of 53%, with significant contributions from third-party RLS sales.
- Adjusted EBITDA was $21.1 million, reflecting an increase in operating expenses due to strategic acquisitions and R&D investments.
- The company invested $81.6 million in R&D, focusing on late-stage therapeutics and precision medicine.
- Despite a reported loss before tax of $4.8 million, Telix achieved positive operating cash flow of $17.7 million.
- Telix's Precision Medicine segment revenue increased by 30% year-over-year, largely due to Illuccix dose volumes.
- The company has expanded its global manufacturing operations and is focusing on new product launches in Europe.
- RLS Radiopharmacies in the U.S. are central to Telix's manufacturing strategy, contributing significantly to revenue.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$5,522 |
Telix H1 2025 Results Announcement
|
21 Aug 2025 8:28AM |
$16.920 |
$16.270 |
fallen by
3.84%
|
|
TLX - Price-sensitive ASX Announcement
Full Release
Key Points
- Telix Pharmaceuticals Limited reports H1 2025 revenue of $390.4 million, a 63% increase from the previous year.
- Gross profit margin stands at 53%, reflecting a change in product mix.
- Adjusted EBITDA is $21.1 million, impacted by increased operating expenditures.
- R&D investment increased by 47% to $81.6 million, focusing on late-stage assets.
- Telix reported a loss before tax of $4.8 million.
- Cash reserves are at $207.2 million, post strategic M&A investments.
- Precision Medicine segment revenue increased by 30%, driven by Illuccix dose volumes.
- Investment in Telix Manufacturing Solutions (TMS) to scale operations.
- RLS, as part of TMS, recorded $109.5 million in revenue.
- Key milestones include advancements in TLX591, TLX592, TLX101, and TLX090 therapeutic programs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pengana International Equities Limited (PIA) ORDINARY FULLY PAID |
Financials |
$344 |
Corporate Governance Statement 30 June 2025
|
21 Aug 2025 8:28AM |
$1.220 |
$1.335 |
risen by
9.43%
|
|
| National Storage REIT (NSR) ORDINARY FULLY PAID |
Real Estate |
- |
NSR 2025 Annual Report
|
21 Aug 2025 8:28AM |
$2.440 |
$2.790 |
risen by
14.34%
|
|
| Charter Hall Group (CHC) STAPLED SECURITIES US PROHIBITED |
Real Estate |
$10,567 |
FY25 Results - Presentation
|
21 Aug 2025 8:28AM |
$22.820 |
$22.340 |
fallen by
2.10%
|
|
Call 1300 880 160
Start a chat
Schedule a call
